128 results on '"Cortes, Jorge E."'
Search Results
2. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
3. POSTER: CML-511 T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML)
4. CML-511 T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML)
5. Teledermatology for skin cancer screening in rural Georgia utilizing teledermoscopy and distance learning: An ongoing report
6. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
7. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
8. Poster: CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
9. Poster: ALL-471 Long-Term Results of the Treatment of Adolescents and Adults With Acute Lymphoblastic Leukemia With a Pediatric-Inspired Regimen Delivered on an Outpatient Basis: A Single Institution Experience
10. CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI)
11. Poster: CML-413 Efficacy and Safety of Bosutinib Versus Imatinib in US Patients With Newly Diagnosed Chronic Myeloid Leukemia After 5-Years Follow-Up in the
12. Poster: CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI)
13. ALL-471 Long-Term Results of the Treatment of Adolescents and Adults With Acute Lymphoblastic Leukemia With a Pediatric-Inspired Regimen Delivered on an Outpatient Basis: A Single Institution Experience
14. CML-413 Efficacy and Safety of Bosutinib Versus Imatinib in US Patients With Newly Diagnosed Chronic Myeloid Leukemia After 5-Years Follow-Up in the BFORE Trial
15. CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update
16. Poster: CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial
17. ME12 IDH Inhibitors in AML
18. SY31-1 Molecular targeted therapy with FLT3 inhibitor in AML
19. Academic Center Outreach to Community Practices Increases Transplant Referrals and Possibly Reduce Racial Disparities
20. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias
21. CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
22. Poster: CML-081: Effect of Comorbidities on Response Outcomes With First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION
23. CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)
24. Poster: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)
25. Oral Abstract: CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)
26. CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study
27. Poster: CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
28. CML-081: Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION
29. Poster: CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study
30. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
31. Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders
32. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
33. CML-023: Relationship Between High Body Mass Index (BMI) and Treatment Outcomes in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Dasatinib or Imatinib: Retrospective Analysis of the Phase 3 DASISION Trial
34. AML-140: Effect of Early Blood Counts on Response and Overall Survival Following Glasdegib Plus LDAC in Newly Diagnosed AML: BRIGHT AML 1003 Post Hoc Analysis
35. AML-043: Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up
36. Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis
37. Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis
38. Clinical Outcomes and Characteristics of Patients (pts) with FLT3–Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial
39. Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission
40. Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results
41. Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial
42. Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study
43. Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial
44. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
45. Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation
46. Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial
47. Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
48. Glasdegib with LDAC in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Unsuitable for Intensive Chemotherapy: Effects on Transfusions and Marrow Recovery vs LDAC Alone
49. Pooled Clinical Safety Analysis of CPX-351 Versus Conventional Chemotherapy in Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
50. Pulmonary Hypertension in Cancer Patients Treated with Tyrosine Kinase Inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.